# Clinical Study of Single Dose IL-6R mAb Injection in RA Patients

> **NCT05232396** · PHASE1 · COMPLETED · sponsor: **Beijing VDJBio Co., LTD.** · enrollment: 40 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** IL-6R Monoclonal Antibody Injection 4mg/kg
- **BIOLOGICAL:** IL-6R Monoclonal Antibody Injection 6mg/kg
- **BIOLOGICAL:** IL-6R Monoclonal Antibody Injection 8mg/kg
- **BIOLOGICAL:** Tocilizumab Injection 8mg/kg

## Key facts

- **NCT ID:** NCT05232396
- **Lead sponsor:** Beijing VDJBio Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-02
- **Primary completion:** 2021-10-27
- **Final completion:** 2022-02-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05232396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05232396, "Clinical Study of Single Dose IL-6R mAb Injection in RA Patients". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05232396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*